Clinical Recurrence Risk Assessment
This tool aggregates commonly used clinicopathologic variables to approximate recurrence risk. Use alongside genomic assays and multidisciplinary guidance.
Tumor size
Lymph node involvement
Tumor grade
Hormone receptor status
HER2 status
Total risk score
—
Risk category
Incomplete data
Estimated recurrence rate
—
How to Use This Calculator
Collect pathology data
Ensure accurate tumor size, nodal status, grade, ER/PR, HER2, and Ki-67 information from the pathology report.
Enter patient demographic details
Age at diagnosis influences recurrence risk and guides adjuvant therapy decisions.
Interpret results within context
This clinical score provides an approximation. Use in combination with genomic assays and multidisciplinary recommendations.
Formula
Score = Age points + Tumor size points + Node points + Grade points + Hormone receptor points + HER2 points + Ki-67 points
Age: <40 = 2, 40–59 = 1, ≥60 = 0
Tumor size: <1 cm = 0, 1–2 cm = 1, 2–5 cm = 2, ≥5 cm = 3
Nodes: 0 = 0, 1–3 = 2, ≥4 = 4
Grade: 1 = 0, 2 = 1, 3 = 2
Hormone receptors: ER/PR positive = −1, ER/PR negative = +1
HER2: Negative = 0, Positive = +1
Ki-67 (%): <10 = 0, 10–20 = 1, 21–30 = 2, >30 = 3
Full Description
Clinical-pathologic factors strongly influence breast cancer recurrence risk. Tumor size, nodal involvement, grade, proliferative index, hormone receptor status, and HER2 expression are core determinants of adjuvant therapy planning. This calculator synthesizes these variables to highlight low, intermediate, or high risk scenarios. Final treatment decisions should integrate genomic risk assays (e.g., Oncotype DX, MammaPrint), patient preferences, comorbidities, and guideline recommendations.
Frequently Asked Questions
Does this replace genomic assays?
No. Genomic tests provide validated recurrence probabilities. Use this calculator as a complementary clinical assessment.
How should triple-negative cancers be handled?
Triple-negative status generally results in higher scores due to hormone receptor negativity and high Ki-67. Systemic chemotherapy is standard.
What about premenopausal vs postmenopausal patients?
Age and hormone status account for some differences. Additional risk modifiers (e.g., ovarian suppression) require individualized evaluation.
Can I use this for metastatic disease?
No. This tool is intended for early-stage, surgically resected disease when assessing adjuvant therapy considerations.